Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | ILK | Q13418 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707208 | 0.86 | NPC1 (0.45) | ACACBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20047521 | 0.83 | ACACB (0.37) | ACACBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL86109 | 0.78 | GAA (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL12205823 | 0.78 | NPC1 (0.38) | ACACBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4788348 | 0.78 | DYRK1A (0.49) | ILK | |
| SCHEMBL2609443 | 0.78 | GFER (0.56) | ALDH1A1MAPTPKMMAPK1 | |
| SCHEMBL2756559 | 0.77 | SMN1; SMN2 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL13729643 | 0.77 | GLP1R (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL24466885 | 0.76 | HSD17B10 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL21422893 | 0.74 | GAA (0.44) | ACACBNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130602-A1 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2023-04-27 | — | — | US | disclosed |
| US-20230130602-A1 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130602-A1 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | CDC37, SI, DAD1 | ACACB 762/4885NPC1 727/4885RAB9A 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.